Key facts
- Iom Bioworks’s last known valuation is $3.3M (Mar 2025).
- It has raised $460K; the latest was Seed Round ($460K) in Mar 2025.
- Notable investors include Inflection Point Ventures (India), FirstPort Capital, Centre for Cellular And Molecular Platforms.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Iom Bioworks
- ·The full record, as it builds
Funding rounds
No funding rounds for Iom Bioworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iom Bioworks
Operator of a microbiome-based therapeutic platform intended to improve health by targeting and modulating specific gut bacteria. The company offers integrated metagenomic modeling, in silico simulations, systems biology, and microbial process engineering, enabling researchers and healthcare providers to develop personalized interventions based on individual microbiome profiles.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2022
- Employees
- 22
- Website
- iombio.com/
- Ownership
- Privately Held (backing)
Iom Bioworks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iom Bioworks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iom Bioworks in its N-PORT filings yet. We sweep new filings monthly.